

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Glycan recognition on HIV env by broadly neutralizing antibodies (bNAbs)	<p>Crystal structure analysis of bNAbs complexed with glycans of HIV env could guide the development of antibody vaccines against HIV infection. The cocrystal structure of the Fab of a previously reported bNAb complexed with HIV gp120 identified prominent binding interactions of the Fab with an oligomannose glycan linked to N332 of gp120 and a protein segment at the V3 loop base of gp120. The crystal structure also showed that the bNAb recognizes the ³²⁴GDIR³²⁷ region at the V3 loop base. Next steps could include using the crystal structure to design optimized bNAbs for candidate HIV vaccines.</p> <p>SciBX 7(40); doi:10.1038/scibx.2014.1192 Published online Oct. 16, 2014</p>	Patent and licensing status unavailable	<p>Garces, F. <i>et al. Cell</i>; published online Sept. 25, 2014; doi:10.1016/j.cell.2014.09.009 Contact: Ian A. Wilson, The Scripps Research Institute, La Jolla, Calif. e-mail: wilson@scripps.edu Contact: Dennis R. Burton, same affiliation as above e-mail: burton@scripps.edu</p>